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Israel and 9) Section of Infectious Diseases, Laniado Medical Center, Netanya, afﬁliated with the Faculty of Medicine, Technion Institute of Technology, Haifa, IsraelAbstractLittle is known about the molecular epidemiology of Klebsiella pneumoniae carbapenemase-producing Escherichia coli (KPCEC). We aimed to
describe the clonal structure and resistance mechanisms of KPCEC in a multicenter study. The study included 88 isolates from four medical
centres in Israel: Tel Aviv Medical Center (n = 17), Laniado Medical Center (n = 12), Sha’are-Zedek Medical Center (n = 38), and Rambam
Medical Center (n = 21). Twelve (14%) KPCEC were from clinical sites and 86% from surveillance cultures. The clonal structure was studied
by pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus sequence typing (MLST) and was highly diverse, with 79 and 45 different PFGE types
and STs, respectively. The most common clones were ST-131 and ST-410, identiﬁed in 21 isolates (23%). Dominant clonal complexes (CCs)
were CC131 (n = 16), CC410 (n = 14), CC10 (n = 17), and CC-69 (n = 6). The blaKPC-2 and blaKPC-3 genes were identiﬁed in 68 and 20
isolates, respectively. All isolates were non-susceptible to ertapenem; 16 (18%) and 35 (40%) isolates were susceptible (minimal inhibitory
concentration 1 mg/L) to imipenem and meropenem, respectively. Isolates were susceptible to colistin, amikacin, ciproﬂoxacin,
gentamicin, and trimethoprim-sulfamethoxazole in 100%, 87%, 28%, 27%, and 21% of the cases, respectively. blaKPC-Harbouring plasmids
from Tel Aviv Medical Center as well as from six CC-131 isolates from the other centres were studied by Inc and pMLST typing. Sixteen
of the 20 blaKPC2-harbouring plasmids were of identical type, IncN-pMLST ST-15. In conclusion, the clonal structure of KPCEC in Israel
is characterized by the predominance of known international extended-spectrum β-lactamase-producing clones and by high intra- and
inter-institutional diversity. This suggests that in Israel, clonal spread does not play a major role in the dissemination of KPCEC.
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p://dx.doi.org/10.1016/j.cmi.2014.10.008IntroductionSince the beginning of the millennia, carbapenemase-producing
Enterobacteriaceae (CPE) have become a major problem in
healthcare systems worldwide. In Israel, a nation-wide epidemic
of CPE was noted in 2006 that was caused mainly due to the
spread of Klebsiella pneumoniae carbapenemase (KPC)-ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Adler et al. KPC-E. coli in Israel 231producing Klebsiella pneumoniae (KPCKP) [1]. Both initial re-
ports [2] and subsequent studies [3] have identiﬁed sequence
type (ST)-258 as the main culprit of this epidemic, suggesting
that clonal spread has been the main mode for the dissemina-
tion of KPC. In contrast, initial reports of KPC-producing
Escherichia coli (KPCEC) [4] and Enterobacter species [5]
showed mainly polyclonal spread. Of particular importance
and concern is the transfer of the blaKPC gene into global
epidemic clones, such as the ST-131 E. coli strain. Unlike the
almost universal predilection for healthcare settings of KPCKP
[6], the ST-131 E. coli strain has been known to be present in
the community as well [7]. Indeed, there have been several
reports from different countries of KPCEC of the ST-131
clones [8,9], but overt outbreaks or community-acquired
cases have never been reported. The main objective of this
study was to examine the molecular epidemiology of KPCEC in
an attempt to elucidate its transmission mode and to compare
its clonal structure to E. coli isolates with other resistant traits.
Therefore, we initiated a multicentre study in four general
hospitals in Israel. We also aimed to study the resistance
mechanisms and the antimicrobial resistance patterns of these
isolates in order to explore the possible treatment options in
these cases.MethodsStudy design and settings
This was a retrospective, multicentre, microbiological study of
KPCEC isolates in Israel. Four medical centres participated in
this study: 1) Laniado Medical Center (LMC), a 400-bed general
hospital in Netanya (Central Israel); 2) Rambam Medical Center
(RMC), a 940-bed tertiary hospital in Haifa (Northern Israel); 3)
Sha’are-Zedek Medical Center (SZMC), a 700-bed general
hospital in Jerusalem, and 4) Tel Aviv Sourasky Medical Center
(TASMC), a 1400-bed tertiary hospital in Tel Aviv. These
centres represent approximately 20% of all Israeli acute hospital
beds. The Clinical Microbiology laboratories were asked to
submit all available patient-unique KPCEC isolates from January
2009 until June 2012 to the National Center for Infection
Control lab for molecular analysis.
In all centres, patients infected or colonized by CPE were put
under contact isolation and were cohorted in separate rooms,
according to the national Israeli guidelines [1].
Microbiological methods
Rectal surveillance cultures were performed using either Mac-
Conkey agar with imipenem 1 mg/L (TASMC) or CHROMagar
KPC agar (Hylabs, Rehovot, Israel) (LMC, RMC, SZMC) as se-
lective media, as previously described [10]. Identiﬁcation andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyantimicrobial susceptibility testing (AST) of bacterial strains was
performed by either manual biochemical assays or disk diffusion
testing (SZMC) or by the VITEK-2 system using GN-ID and
GN09 cards (bioMerieux, Marcy l’Etoile, France) (LMC, RMC,
TASMC). Ertapenem, imipenem, and meropenem minimal
inhibitory concentrations (MIC) were tested at the National
Center for Infection Control lab by agar dilution [11], and colistin
MIC was tested by E-test (bioMerieux, Marcy l’Etoile, France).
Susceptibility was determined using MIC breakpoints of the
Clinical and Laboratory Standards Institute 2013 criteria [12].
Molecular methods
Isolates were initially tested by blaKPC-polymerase chain reac-
tion (PCR) [13]. The blaKPC allele was determined by
sequencing. All KPCEC isolates were also tested by blaOXA-48,
blaNDM, blaVIM, and blaIMP by PCR [14,15]. The blaCTX-M, blaTEM,
and blaSHV extended-spectrum β-lactamase (ESBL) genes were
identiﬁed by PCR and sequencing [16,17]. The genetic relat-
edness between isolates was determined using pulsed-ﬁeld gel
electrophoresis (PFGE) [18], and multilocus sequence typing
(MLST) [19] was performed on every representative PFGE type
and analyzed using the eBURST software [20].
Plasmid analysis
Plasmid DNA was puriﬁed and transformed into E. coli DH10B.
Transformants were selected on LB (Lysogeny broth) agar
supplemented with cefazolin (8 mg/L) and conﬁrmed by blaKPC
-PCR. Determination of plasmid size and restriction-fragment
length polymorphism (RFLP) were done as previously
described [21]. Plasmids were also characterized by Inc typing
[22] and plasmid MLST (pMLST) [23] using the plasmid MLST
Web site (http://pubmlst.org/plasmid/). The genetic environ-
ment surrounding the blaKPC gene was studied by PCR as
described [24].ResultsClonal structure of KPCEC isolates in Israel
There were 88 (71.5%) KPCEC that were available for analysis,
out of a total of 123 that were isolated during that period: 38/38
(100%) from SZMC, 21/37 (57%) from RMC, 17/27 (63%) from
TASMC, and 12/20 from LMC (60%). Twelve KPCEC were
from clinical sites (blood culture – 1) and 76 were from sur-
veillance cultures.
The STs blaKPC allele and the blaESBL genes of the common
(2) isolates and singletons are presented in Table 1 and
Supplementary Table 1, respectively. The clonal structure was
highly diverse, with 79 and 45 different PFGE types and STs,
respectively. The most common STs were ST-410 and ST-131,and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 230–235
TABLE 1. Sequence types (ST), PFGE types, blaKPC allele, and blaESBL genes of the common (‡2) KPCEC clones in Israel
ST Centres No. of isolates (%) No. of PFGE types blaKPC Allele (no. of isolates) blaESBL Allele (no. of isolates)
ST410 RMC 4 4 2 (4) blaCTX-M-15 (2), no (2)
SZMC 3 2 3 (3) blaCTX-M-14 (1), blaCTX-M-15 (1),
no (1)
TASMC 5 3 2 (5) blaCTX-M-15 (4), no (1)
12 (13.6)
ST131 RMC 3 3a 2 (2), 3 (1) blaCTX-M-15 (2), no (1)
SZMC 3 2a 2 (2), 3 (1) no (3)
TASMC 3 2 2 (3) blaCTX-M-15 (1), blaCTX-M-27 (2)
9 (10.2)
ST69 SZMC 4 4 2 (3), 3 (1) no (4)
TASMC 1 Untypeable 2 (1) no (1)
5 (5.7)
ST10 RMC 1 1 2 (1) no (1)
SZMC 2 2 3 (2) no (2)
TASMC 1 1 2 (1) no (1)
4 (4.5)
ST3329 LMC 2 1a 2 (2) blaCTX-M-15 (2)
SZMC 2 2a 2 (1), 3 (1) blaCTX-M-15 (2)
4 (4.5)
ST167 RMC 1 1 2 (1) no (1)
SZMC 1 1 2 (1) no (1)
TASMC 1 1 3 (1) no (1)
3 (3.4)
ST48 LMC 2 2 2 (2) no (2)
RMC 1 1 2 (1) no (1)
3 (3.4)
ST1431 LMC 1 1 2 (1) blaCTX-M-14 (1)
TASMC 1 1 3 (1) no (1)
2 (2.3)
ST2451 RMC 1 1a 3 (1) blaCTX-M-15 (1)
SZMC 1 1a 3 (1) blaCTX-M-27 (1)
2 (2.3)
ST34 LMC 1 1 2 (1) no (1)
SZMC 1 1 2 (1) no (1)
2 (2.3)
ST354 RMC 1 1 2 (1) no (1)
TASMC 1 1 2 (1) no (1)
2 (2.3)
ST405 RMC 1 1 3 (1) blaCTX-M-9 (1)
SZMC 1 1 2 (1) no (1)
2 (2.3)
ST90 RMC 1 1 3 (1) no (1)
SZMC 1 1 3 (1) no (1)
2 (2.3)
ST93 LMC 1 Untypeable 2 (1) no (1)
SZMC 1 1 2 (1) no (1)
2 (2.3)
ST46 RMC 2 (2.3) 1 2 (2) no (2)
ST604 TASMC 2 (2.3) 1 2 (2) blaSHV-12 (2)
ST617 SZMC 2 (2.3) 1 2 (2) blaCTX-M-15 (1), no (1)
KPCEC, Klebsiella pneumoniae carbapenemase-producing Escherichia coli; LMC, Laniado Medical Center; PFGE, pulsed-ﬁeld gel electrophoresis; RMC, Rambam Medical Center;
SZMC, Sha’are-Zedek Medical Center; TASMC, Tel Aviv Medical Center.
aSimilar PFGE type present in two centres.
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These two STs were present in three of the centres and
exhibited diverse PFGE patterns. Also, these STs were part of
clonal complexes (CCs) 131 (STs 131, 2451, 3329, and 3730,
n = 16) and 410 (STs 410 and 90, n = 14). Only three PFGE
types were present in more than one centre, all from CC-131
(STs 131, 2451, and 3329). Additional dominant CCs were CC-
10 (STs 10, 34, 48, 167, 617, 744, 3734, and 3742, n = 17) and
CC-69 (STs 69 and 3389, n = 6). There were 28 singleton STs,
mostly in SZMC (Supplementary Table 1).
Molecular and microbiological characteristics of
antimicrobial resistance of KPCEC isolates in Israel
The blaKPC-2 and blaKPC-3 genes were identiﬁed in 68 and 20
isolates, respectively. Both blaKPC-2 and the blaKPC-3 alleles were
identiﬁed in all major STs (>3 isolates) and were present at the
same centre. The blaESBL genes were found in 28 isolates, mostClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcommonly blaCTX-M-15 (n = 19) and blaCTX-M-27 (n = 3), with
variable presentation in the same ST (Table 1).
The AST results according to CCs are presented in Table 2.
All isolates were non-susceptible (MIC >0.5 mg/L) to ertape-
nem; 16 (18%) and 35 (40%) isolates were susceptible (MIC
1 mg/L) to imipenem and meropenem, respectively. There
were no signiﬁcant differences in the MIC of carbapenems
among the different CCs. Isolates were susceptible to colistin,
amikacin, ciproﬂoxacin, gentamicin, and trimethoprim-
sulfamethoxazole in 100%, 87%, 28%, 27%, and 21% of the
cases, respectively.
blaKPC-Harbouring plasmids of KPCEC isolates in
TASMC
In light of the wide diversity of the PFGE types, we decided to
explore the role of horizontal gene transfer (HGT) as a mode for
dissemination of KPCEC, by characterizing the blaKPC-ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 230–235
TABLE 2. Antimicrobial susceptibility testing results according to clonal complexes (CC)
Clonal
complexa Isolates no.
Ertapenem
(median, IQR, range)
Imipenem
(median, IQR, range)
Meropenem
(median, IQR, range)
Gentamicin
susceptible
n (%)
Amikacin
susceptible
n (%)
Ciproﬂoxacin
susceptible
n (%)
TMP-SFX
susceptible
n (%)
Colistin
susceptible
n (%)
CC10 17 4, 2–8, 1–32 2, 2, 0.5–16 2, 1–4, 0.5–8 7 (41.2) 16 (94.1) 8 (47.1) 3 (17.6) 17 (100)
CC131 16 8, 4–16, 2–32 2, 2–4, 1–8 2, 1–4, 1–4 2 (12.5) 13 (81.2) 2 (12.5) 3 (18.7) 16 (100)
CC410 14 4, 4–8, 1–32 2, 2–8, 1–16 2, 1–4, 0.5–8 7 (50) 10 (71.4) 0 4 (28.6) 14 (100)
CC69 6 4, 4–8, 4–8 4, 4–8, 2–16 2, 2, 0.5–2 2 (33.3) 6 (100) 5 (83.3) 2 (33.3) 6 (100)
Other 35 4, 4–16, 1–32 4, 2–4, 1–16 2, 1–4, 0.5–16 6 (17.1) 32 (91.4) 13 (37.1) 7 (20) 35 (100)
IQR, interquartile range; TMP-SFX, trimethoprim sulfamethoxazole.
aThe STs included in each CC are listed in the text.
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this task, we decided to include in our analysis all of the isolates
of a single centre, TASMC. In addition, we included all the blaKPC-
2-harbouring plasmids of CC-131 from the other three centres
(two each) (Table 3). Of note, KPCKP was isolated in addition to
KPCEC in six of the 17 patients (the isolates were not available
for analysis). Although most plasmids were of different size and
RFLP patterns, 12 of the 14 (85%) blaKPC-2-harbouring plasmids
from TASMC and all of the CC-131 isolates from the other
centres belonged to a single type, IncN-ST15; this type was
identiﬁed as early as 2009 and throughout the duration of the
study. In contrast, each of the 3 blaKPC-3-harbouring plasmids
was of distinct Inc/pMLST type. The blaKPC-3-harbouringTABLE 3. Characteristics of blaKPC-harbouring plasmids in
KPCEC isolates
Isolate no. ST1
blaKPC
allele Size (kb)
RFLP
identity Inc type pMLST
TASMC
76 410 2 65 A N 15
77 69 2 48 + 55a NA N 15
78 38 2 65 NA N 15
79 1463 3 85 NA FIIs F18:A-:B1
80 1431 3 45 NA Unidentiﬁed
81 410 2 48.5 B N 15
82 410 2 48.5 B N 15
83 167 3 20 + 315a NA HI2 Unidentiﬁed
84 131 2 50 C N 15
85 410 2 50 C N 15
86 604 2 50 C N 15
87 131 2 55 NA HI2 1
88 410 2 50 C N 15
89 354 2 65 A N 15
90 10 2 48.5 NA N 15
91 604 2 20 + 210a NA HI2 1
92 131 2 50 C N 15
RMC, LMC and SZMC
4 3329 2 65 A N 15
6 3329 2 55 NA N 15
17 131 2 50 NA N 15
18 131 2 65 NA N 15
60 131 2 ~50b NA N 15
68 131 2 100 NA N 15
KPCEC, Klebsiella pneumoniae carbapenemase-producing Escherichia coli; LMC,
Laniado Medical Center; NA, not applied or unique pattern; pMLST, plasmid multi-
locus sequence typing; RFLP identity, an identical restriction-fragment length
polymorphism pattern between the listed plasmids; smr0018 allele-1, smr0199
allele undetected; RMC, Rambam Medical Center; ST, sequence type; SZMC,
Sha’are-Zedek Medical Center; TASMC, Tel Aviv Medical Center.
The plasmid analysis was performed for: (a) all TASMC isolates; (b) blaKPC-2-
harboring plasmids from clonal complex 131 isolates of the other centres.
aDenotes that two plasmids were inseparable following transformation.
bApproximate size due to blurred visibility.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyplasmid pKpQIL that was commonly identiﬁed in the epidemic
ST-258 K. pneumoniae clone in Israel [3] and its pMLST type
(IncFII-pMLST-K2) were not represented in this collection. We
also analysed the genetic environment surrounding the blaKPC-2
gene in isolate 76. The gene was located inside a truncated
Tn4401 transposon, as was recently described in other blaKPC-2-
harbouring plasmids in our institution [24].DiscussionThis article presents the ﬁrst multicentre study of KPCEC and
the largest molecular study of any CPE other than
K. pneumoniae. Previous reports of KPCEC were limited to
single-centre series of small numbers of isolates [4,8,9,25,26].
Therefore, our study provides the ﬁrst opportunity for a
comprehensive outlook of the clonal structure of KPCEC. The
MLST analysis, even though typically less discriminative than
PFGE [27], showed a highly diverse population including 28
singletons. This analysis also highlighted the predominance of
known global ESBL-producing E. coli clones, such as ST-131, ST-
410, ST-69, and ST-10, that were previously reported both
internationally [27] and from Israel [28]. This ﬁnding is alarming
because the presence of the blaKPC gene in these clones in-
dicates presumably the potential for its dissemination. Despite
that, the PFGE analysis showed that similar PFGE patterns,
suggesting the possibility of clonal spread, were found in only
nine of the 88 isolates (10%). Interestingly, inter-institutional
presence of strains with identical PFGE patterns were found
in only three strains, all of them part of the CC-131 (ST-131,
-3329, and -2451), indicating its transmissibility potential.
Together, the clonal studies using both PFGE and MLST data
suggest that clonal spread is unlikely to play a major role in the
dissemination of KPCEC.
In contrast with the predominance of blaKPC-3allele that was
typically found in ST-258 KPCKP in Israel [29], the dominant
allele in KPCEC was blaKPC-2 (68/88, 77%), as was previously
reported in E. coli and Enterobacter spp. in Israel [4,5]. The
plasmid analysis provides a plausible explanation for thisand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 230–235
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most of the blaKPC-2 harbouring plasmids in TASMC (12/14), as
well as all of the plasmids from CC-131, were related to a single
type, IncN, pMLST ST-15. Similar ﬁndings were found in six
KPC-2 producing E. coli and nine K. pneumoniae isolated before
2009 [24]. Together, these ﬁndings support the hypothesis that
HGT plays an important role in the dissemination of the blaKPC-
2 gene in KPCEC. The absence of the pKpQIL or related type
plasmids, even in the blaKPC-3-harbouring plasmids, suggests that
this epidemic is likely to be independent of the main clonal
epidemic of ST-258 KPCKP.
The blaESBL repertoire found included mainly commonly
found genes [30], such as blaCTX-M-15 and blaCTX-M-27. ESBLs
were identiﬁed in only a minority of the isolates (28/88; 32%),
suggesting that acquisition of blaKPC had occurred independent
of the presence of ESBL. It is intriguing that, despite the fact that
ESBLs were identiﬁed in known global ESBL-producing clones
(e.g. STs-131, -410, -69), some of the isolates of these clones
lacked ESBL: four of the 12 ST-410 isolates, four of the nine ST-
131 isolates, and all ﬁve of the ST-69 isolates. Because the clonal
structure of wild-type E. coli is largely unknown, this ﬁnding may
have two explanations—either that these clones are also
common in the wild-type population, or that they possess an
innate propensity for the acquisition and maintenance of anti-
microbial resistance genes.
Additional important differences between the KPCEC and the
KPCKP populations in Israel are related to AST proﬁle. The car-
bapenem MIC values in KPCEC were strikingly lower compared
with KPCKP [21], with a signiﬁcant proportion (40%) fully sus-
ceptible (MIC 1 mg/L) to meropenem. In addition, almost all of
the isolates were susceptible to amikacin (in addition to colistin),
and around a quarter of the isolates were susceptible to cipro-
ﬂoxacin, gentamicin, and trimethoprim-sulfamethoxazole, in
contrast with the resistance proﬁle of the epidemic KPCKP clone
[1,2]. These ﬁndings suggest that more therapeutic options exist
to treat KPCEC than to treat KPCKP, and that either non-β-lac-
tam antimicrobials or high-dosemeropenemmay be used to treat
these infections.
Our study has several limitations, especially concerning
some of its objectives that have gone beyond a merely
descriptive analysis. We concluded that clonal spread is un-
likely to be the main dissemination mode of KPCEC. Although
this conclusion is somewhat compromised by the absence of
some of the KPCEC isolates in our collection, we believe that
because most isolates were indeed included and the striking
difference between the clonal diversity of KPCEC compared
with KPCKP, this conclusion is justiﬁed. The ability to sub-
stantiate the role of HGT as the main mode of transmission is
understandably much more difﬁcult with the current design.
First, due to the demanding and time-consuming nature of theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectanalysis, we were able to analyse all of the isolates of one
centre only, with limited representation of the other centres.
Second, the role of HGT in the transmission of blaKPC has
been argued in cases where such a phenomenon was sug-
gested by epidemiological data, e.g. when more than a single
KPC-producing Enterobacteriaceae species was isolated in a
single patient [31] or during an outbreak [32]. The design of
our study naturally precludes such epidemiological tracking.
Nevertheless, through the use of Inc typing and pMLST
(rather than merely size measurement and RFLP) in the
TASMC isolates, we were able to suggest a possible molecular
mechanism that underlies the link between the unrelated
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